C2N Diagnostics

Executive Summary

C2N Diagnostics is a private, Phase 3-stage diagnostics company focused on Alzheimer’s disease, with its lead product PrecivityAD—a blood test designed to detect amyloid plaques and facilitate early diagnosis. The company aims to replace costly and invasive PET scans and spinal taps with a widely accessible, cost-effective blood test. C2N's technology leverages mass spectrometry and proprietary biomarkers to provide accurate results, potentially transforming Alzheimer’s screening and monitoring. With the growing prevalence of Alzheimer’s and recent FDA approvals of anti-amyloid therapies, the demand for reliable diagnostic tools is surging. C2N is well-positioned to capture this market, though it faces competition from other blood test developers like Quest Diagnostics and Roche. The company's success hinges on regulatory clearance, payer reimbursement, and clinical adoption. Its recent Series B fundraising and partnerships underscore investor confidence, but as a private firm, financial details remain opaque.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance or breakthrough designation for PrecivityAD80% success
• Q4 2026Major Medicare or commercial payer coverage decision60% success
• Q2 2026Publication of pivotal Phase 3 clinical validation results in peer-reviewed journal90% success